Nektar Reorganizes To Position Pegylated, Pulmonary Units For Future Development
This article was originally published in The Pink Sheet Daily
Executive Summary
Spending cuts amounting to $65 million annually are not driven by lackluster performance of Exubera, CEO Robin maintains.